Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb;67(2):301-319.
doi: 10.1007/s11427-023-2369-3. Epub 2023 Oct 18.

Modeling drug-induced mitochondrial toxicity with human primary cardiomyocytes

Xiaoli Tang  1 , Hong Liu  1 , Rongjia Rao  1 , Yafei Huang  1 , Mengqi Dong  1 , Miaomiao Xu  1 , Shanshan Feng  1 , Xun Shi  1 , Li Wang  1   2 , Zengwu Wang  1   3 , Bingying Zhou  4   5
Affiliations

Modeling drug-induced mitochondrial toxicity with human primary cardiomyocytes

Xiaoli Tang et al. Sci China Life Sci. 2024 Feb.

Abstract

Mitochondrial toxicity induced by therapeutic drugs is a major contributor for cardiotoxicity, posing a serious threat to pharmaceutical industries and patients' lives. However, mitochondrial toxicity testing is not incorporated into routine cardiac safety screening procedures. To accurately model native human cardiomyocytes, we comprehensively evaluated mitochondrial responses of adult human primary cardiomyocytes (hPCMs) to a nucleoside analog, remdesivir (RDV). Comparison of their response to human pluripotent stem cell-derived cardiomyocytes revealed that the latter utilized a mitophagy-based mitochondrial recovery response that was absent in hPCMs. Accordingly, action potential duration was elongated in hPCMs, reflecting clinical incidences of RDV-induced QT prolongation. In a screen for mitochondrial protectants, we identified mitochondrial ROS as a primary mediator of RDV-induced cardiotoxicity. Our study demonstrates the utility of hPCMs in the detection of clinically relevant cardiac toxicities, and offers a framework for hPCM-based high-throughput screening of cardioprotective agents.

Keywords: cardiotoxicity; high-throughput screening; human primary cardiomyocytes; mitochondrial toxicity; remdesivir.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Abi-Gerges, N., Indersmitten, T., Truong, K., Nguyen, W., Ratchada, P., Nguyen, N., Page, G., Miller, P.E., and Ghetti, A. (2020a). Multiparametric mechanistic profiling of inotropic drugs in adult human primary cardiomyocytes. Sci Rep 10, 7692. - PubMed - PMC - DOI
    1. Abi-Gerges, N., McMahon, C., Vargas, H., Sager, P., Chui, R., Stevens, D., Davila, J., Schaub, J.R., Wu, J.C., del Rio, C., et al. (2019). The West coast regional safety pharmacology society meeting update: Filling translational gaps in safety assessment. J Pharmacol Toxicol Methods 98, 106582. - PubMed - DOI
    1. Abi-Gerges, N., Miller, P.E., and Ghetti, A. (2020b). Human heart cardiomyocytes in drug discovery and research: new opportunities in translational sciences. Curr Pharm Biotechnol 21, 787–806. - PubMed - DOI
    1. Agency, E.M. (2020). Summary on Compassionate Use. Remdesivir Gilead. Available from URL: https://www.ema.europa.eu/en/documents/other/summary-compassionate-use-r... .
    1. Appu, G.V., Joshi, D.A., Bavage, S.B., and Bavage, S.B. (2021). Adverse drug event reporting of remdesivir. Int J Innov Res Technol 8, 159–161.

LinkOut - more resources